TD Cowen raised the firm’s price target on Regeneron to $1,030 from $1,020 and keeps a Buy rating on the shares. The firm updated its model and increased their Eylea
TD Cowen raised the firm’s price target on Regeneron to $1,030 from $1,020 and keeps a Buy rating on the shares. The firm updated its model and increased their Eylea
הפירמה עדכנה את מודל הפיננסים שלה, והעלתה את תחזיותיה למכירות Eylea HD. כמו כן, הם העלו את הערכות המכירות שלהם עבור Dupi ו-Libtayo בהתבסס על ניתוח נתוני המרשמים מ-IQVIA.
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,016.00. The company’s shares closed
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ClearPoint Neuro (CLPT – Research Report), Legend Biotech (LEGN – Research Report) and Regeneron (REGN – Research Report) with bullish sentiments.
ClearPoint Neuro (CLPT)
In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on ClearPoint Neuro. The company’s shares closed last Tuesday at $5.58.
According to TipRanks.com, Takkinen is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ClearPoint Neuro with a $9.50 average price target.
See the top stocks recommended by analysts >>
Legend Biotech (LEGN)
Jefferies analyst Kelly Shi maintained a Buy rating on Legend Biotech today and set a price target of $93.00. The company’s shares closed last Tuesday at $50.12.
According to TipRanks.com, Shi is a 1-star analyst with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $86.58, a 73.2% upside from current levels. In a report issued on April 3, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $82.00 price target.
Regeneron (REGN)
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Regeneron, with a price target of $1060.00. The company’s shares closed last Tuesday at $894.14.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $1037.84 average price target, representing a 15.7% upside. In a report issued on April 4, RBC Capital also maintained a Buy rating on the stock with a $1189.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLPT: